Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...
The funding review is part of a broader government push to examine spending on messenger RNA-based vaccines, the technology that Moderna and Pfizer used to develop their COVID-19 vaccines.
"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our ...
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
A small study on Covid vaccine safety has sparked an online tempest — and highlighted the conundrum faced by some scientists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback